 The primary objective of the study is to determine bioequivalence of 50 mg 2x25 mg Artesunate Sachet Pfizer versus 50 mg 1x50 mg tablet, Arsuamoon Guilin China which is the World Health Organization Reference standard for artesunate The secondary objective is to assess the safety of Artesunate Sachet Pfizer and Arsuamoon tablet Guilin China. 